Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. reports developments across its biotechnology medicines business, including discovery, development, manufacturing and delivery of human therapeutics. Company updates center on a portfolio and pipeline spanning cancer, inflammatory conditions, rare diseases, heart disease, obesity and obesity-related conditions, with named products and programs such as TEPEZZA, Repatha and IMDELLTRA appearing in clinical and commercial announcements.
Recurring news also covers quarterly financial results, non-GAAP performance measures, manufacturing network investments, supply-chain capacity, research collaborations, medical and investor conference presentations, and executive or organizational changes tied to the integration of biology, technology, artificial intelligence and data across Amgen's operations.
Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026 at 9:20 a.m. ET. Peter Griffith, CFO, and Jasper van Grunsven, SVP of Rare Disease, will take part in a fireside chat. The event will be webcast live and archived for at least 90 days.
The webcast will be available to media, investors, and the public via Amgen's Investor Relations Events Calendar and archived on Amgen's website for replay.
Amgen (NASDAQ:AMGN) announced a $2.52 per share cash dividend for the second quarter of 2026. The Board declared the dividend on March 4, 2026, payable on June 5, 2026 to shareholders of record as of May 15, 2026.
Amgen (NASDAQ:AMGN) will present at the 46th Annual TD Cowen Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026. Senior VPs Kave Niksefat (Global Marketing and Access) and Justin Claeys (Finance) will speak.
The presentation will be webcast live and archived for at least 90 days on Amgen's Investor Relations events calendar and webcast page, available to media, investors and the public.
Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit on Wednesday, Feb. 18, 2026 at 12:15 p.m. PT. Jean-Charles Soria, senior vice president of oncology within global development, will deliver the presentation.
The presentation will be webcast live and archived for at least 90 days on Amgen's investor website, with timing and links listed on the Investor Relations Events Calendar.
Amgen (NASDAQ: AMGN) reported Q4 2025 and full-year results on Feb 3, 2026. Total revenues rose 10% year-over-year to $36.8 billion for 2025; product sales increased 10% to $35.15 billion. GAAP EPS was $14.23 for FY 2025 (up 88%); free cash flow was $8.1 billion. The company recorded a $1.2 billion Otezla intangible-asset impairment and reported mixed product performance, including strong growth for Repatha, TEZSPIRE and UPLIZNA and significant declines for Enbrel and other legacy products.
Amgen (NASDAQ:AMGN) will report fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after U.S. market close. A conference call with management will follow at 4:30 p.m. ET, and live audio webcast will be available on Amgen's Investor Relations site.
The webcast will be archived and available for replay for at least 90 days on the company's website.
Summary not available.
Amgen (NASDAQ:AMGN) will present at the 2026 J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Monday, January 12, 2026. Robert A. Bradway, chairman and chief executive officer, will deliver the presentation. The event will be webcast live and available to media, investors and the public via Amgen's website under Investors. Presentation times and webcast links are listed on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
Amgen (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics for up to $840 million on Jan 6, 2026. The deal brings DBT 3757, a MLLT1/3-targeted investigational degrader currently in IND-enabling studies, into Amgen's oncology portfolio for development in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Amgen plans to integrate Dark Blue into its research organization to accelerate clinical advancement. Investors backing Dark Blue included Oxford Science Enterprises, Bristol Myers Squibb, and Evotec; BofA served as financial advisor.
Amgen (NASDAQ: AMGN) announced on Jan 6, 2026 the acquisition of Dark Blue Therapeutics for up to $840 million. The deal adds an investigational small molecule that targets and degrades proteins MLLT1/3, aimed at specific types of acute myeloid leukemia (AML).
Preclinical leukemia models showed promising anti-cancer activity and a mechanism differentiated from current therapies, supporting potential single-agent and combination use to address treatment resistance and durability of remission. Amgen said it will integrate Dark Blue into its research organization to strengthen early oncology discovery and advance the program toward clinical investigation.